(Q38131726)

29 August 2017

title

Toll-like receptors in urothelial cells--targets for cancer immunotherapy (English)

1 reference

29 August 2017

0 references

1 reference

Hélène LaRue

1

1 reference

29 August 2017

Cherifa Ayari

series ordinal

2

1 reference

29 August 2017

Alain Bergeron

series ordinal

3

1 reference

29 August 2017

Yves Fradet

series ordinal

4

1 reference

29 August 2017

language of work or name

English

0 references

publication date

27 August 2013

1 reference

29 August 2017

published in

Nature Reviews Urology

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

537-545

1 reference

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

The health economics of bladder cancer: a comprehensive review of the published literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Urinary bladder urothelium: molecular sensors of chemical/thermal/mechanical stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Mycobacterium bovis BCG Toll-like receptors 2 and 4 cooperation increases the innate epithelial immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Role of neutrophils in BCG immunotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptors in normal and malignant human bladders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Mammalian toll-like receptors: from endogenous ligands to tissue regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor signaling in cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptors and their crosstalk with other innate receptors in infection and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

CD14- and Toll-like receptor-dependent activation of bladder epithelial cells by lipopolysaccharide and type 1 piliated Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Cell biology and physiology of the uroepithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

TLR-mediated immune responses in the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Diagnosis and treatment of uncomplicated urinary tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Uropathogenic Escherichia coli as a model of host-parasite interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Innate and adaptive immune responses in the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Roles of toll-like receptors in cancer: a double-edged sword for defense and offense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Cutting edge: Tlr5-/- mice are more susceptible to Escherichia coli urinary tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor responses of normal human urothelial cells to bacterial flagellin and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

A toll-like receptor that prevents infection by uropathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Lung cancer and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor expression in normal ovary and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

TLR signaling by tumor and immune cells: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Interferon-gamma up-regulates toll-like receptor 4 and cooperates with lipopolysaccharide to produce macrophage-derived chemokine and interferon-gamma inducible protein-10 in human bladder cancer cell line RT4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Targeting pattern recognition receptors in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Targeting Toll-like receptors: emerging therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

The application of Toll like receptors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Guérin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

A delicate dance: host response to mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Control of Mycobacterium bovis BCG infection with increased inflammation in TLR4-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Therapeutic potential of mycobacterial cell wall-DNA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Heat Shock Protein 72 (HSPA1B) Gene Polymorphism and Toll-Like Receptor (TLR) 4 Mutation Are Associated with Increased Risk of Urinary Tract Infection in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Lack of association between the Tlr4 (Lpsd/Lpsd) genotype and increased susceptibility to Escherichia coli bladder infections in female C3H/HeJ mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Urinary tract infections revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Essential role of MD-2 in LPS responsiveness and TLR4 distribution.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor 3 expressed by melanoma cells as a target for therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor 4 gene polymorphisms and susceptibility to bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Mycobacterium bovis bacille Calmette Guerin infection of human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and TLR4 activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guérin by Flt3-ligand generated dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.153

Current views of toll-like receptor signaling pathways

31 March 2020

1 reference

12 December 2020

Interleukin-6 Production by Bladder Tumors is Upregulated by BCG Immunotherapy

1 reference

12 December 2020

Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection

1 reference

12 December 2020

Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide

1 reference

12 December 2020

Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.

1 reference

12 December 2020

Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice

1 reference

12 December 2020

Membrane-anchored CD14 is important for induction of interleukin-8 by lipopolysaccharide and peptidoglycan in uroepithelial cells

1 reference

12 December 2020

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

1 reference

12 December 2020

Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways

1 reference

12 December 2020

In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.

1 reference

12 December 2020

Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro

1 reference

12 December 2020

Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells

1 reference

12 December 2020

Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer

1 reference

12 December 2020

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.153

1 reference

Dimensions Publication ID

29 August 2017

1009573193

0 references

1 reference